Advert for Healthcare Professionals Only
I am a patient (Please go to our patient website)
- All Topics
- Allergy and Clinical Immunology
- Anesthesiology
- Angiology
- Cardiology
- Central Nervous System
- Clinical Laboratory
- Complementary and Alternative Medicine
- Critical Care/Intensive Care
- Dermatology
- Diabetes and Endocrinology
- Ear, Nose and Throat
- Emergency Medicine
- Eye Health and Disorders
- Family Medicine
- Gastroenterology
- Gerontology/Geriatrics
- Haematology
- Hepatology
- HIV/AIDS
- Immunology
- Infectious Diseases
- Internal Medicine
- Kidney and Urological Diseases
- Medical Genetics
- Men's Health, Andrology and Urology
- Musculoskeletal Disorders
- Neonatal/Perinatal Medicine
- Neurological Disorders
- Nutrition and Dietetics
- Oncology
- Orthopaedics
- Paediatrics
- Pain Management
- Palliative Medicine
- Plastic Surgery and Aesthetic Medicine
- Podiatry
- Preventive Medicine
- Psychiatry/Mental Health
- Radiology
- Respiratory
- Rheumatology
- Sexual Health
- Sleep Medicine
- Sports Medicine
- Surgery (General)
- Transplantation
- Tropical Medicine
- Vaccines
- Women's Health and Obs/Gyn
- ADHD
- Alzheimer's Disease
- Arthritis
- Asthma and COPD
- Atopic Dermatitis
- Cholesterol
- Chronic Myeloid Leukemia
- COPD
- Cystic Fibrosis
- Diabetes
- Gastrointestinal Stromal Tumours
- Hepatitis
- Hypertension
- Insomnia
- Lysosomal Storage Disorders
- Men's Health
- Multiple Sclerosis
- Niemann-Pick type C
- Non-small Cell Lung Cancer
- Opioids and Pain
- Parkinson's Disease
- Post-Myocardial Infarction
- Prostate Cancer
- Renal Anaemia
- Renal Cell Carcinoma
- Soft Tissue Sarcoma
- UROKINASE 10,000 I.U.
- STREPTASE 250,000 IU AND 750,000 IU
- WARFARIN TABLETS 3MG B.P.
- WARFARIN TABLETS 1MG
- WARFARIN TABLETS 5MG B.P.
- GRAZAX 75,000 SQ-T ORAL LYOPHILISATE
- GABAPENTIN 100 MG CAPSULES
- FLEET PHOSPHO-SODA
- BONJELA COOL MINT GEL
- PNEUMOVAX II
- DECAPEPTYL SR 3MG
- DECAPEPTYL SR 11.25MG
- FLUDARABINE PHOSPHATE 50 MG POWDER FOR SOLUTION FOR INJECTION OR INFUSION
- PLAVIX 75MG TABLETS
- FRAGMIN - EXTENDED TREATMENT IN ONCOLOGY (5000, 7500, 10000, 12500, 15000, 18000 I.U SYRINGES)
- BACLOFEN TABLETS BP 10MG
- EXELON
- DOXYCYCLINE CAPSULES BP 100MG
- FUROSEMIDE INJECTION BP 10MG/ML, 2ML, 5ML & 25ML
- PHENINDIONE 50MG TABLETS
- LORATADINE 10MG TABLETS
- DICLOFENAC SODIUM 50MG TABLETS
- FLEBOGAMMA (FORMERLY ALPHAGLOBIN)
- CLOPIDOGREL 75 MG FILM-COATED TABLETS
- PHENINDIONE 25MG TABLETS
- CALCICHEW-D3 500 MG/400IU CAPLETS
- AMISULPRIDE 50MG TABLETS
- FLEBOGAMMA DIF 50MG/ML
- CALPOL INFANT SUGAR FREE COLOUR FREE 120 MG/5 ML ORAL SUSPENSION
- DULCOLAX TABLETS, 5MG
- ADHD
- Alzheimers
- Anxiety Disorders
- Arthritis
- Asthma
- Avonex
- Breast Cancer
- Cervical Cancer
- Cholesterol
- Colorectal Cancer
- Copaxone
- Depression
- Diabetes
- Erectile Dysfunction
- Extavia
- Hypertension
- Insomnia
- Men's Health
- Meningitis
- Migraine
- Pain Management
- Parkinson's
- Pharma News
- Post-MI
- Pregnancy
- Prostate
- Rebif
- Renal anaemia
- Renal Cell Carcinoma
- Thrombosis
- Thromboembolism
- Tysabri
Welcome to www.epgonline.org Europe's largest website for Healthcare Professionals (HCPs)
Search the site for any medical term or simply browse by disease topic.
Access all the information you need in one place, when you need it, how you want it and for free!
Share:
 |
HCPs Register now For free unlimited access to all content |
 |
I am a patient (This website is for doctors - please go to our patient website) |
What's new on EPG Online
SGLT2-Inhibitors eCME Webcast – ACCME/EACCME Accredited Programme
Type 2 Diabetes Mellitus affects approximately 20.66 million people across the UK, France, Germany, Spain and Italy1. This leads to many complications including macrovascular and microvascular disease. Glycaemic control in diabetes is particularly important in reducing these complications; a 1% fall in HbA1C results in a 37.5% and 42.5% reduction in microvascular and peripheral vascular disease respectively2
There are numerous treatments for Type 2 Diabetes Mellitus. These act on receptors within various organs including the pancreas, muscle, adipose tissue, gastrointestinal tract and liver. A new class of drugs, SGLT2-Inhibitors act on the kidney, which itself plays an important role in glycaemic control.
The eCME webcast entitled SGLT2-Inhibitors: Assessing the Evidence and the Potential Impact on Future Clinical Practice is ACCME/EACCME accredited. This activity has been designed to inform healthcare professionals on Type 2 Diabetes Mellitus and the role of SGLT2-Inhibitors in the treatment of this disease.
References
1. IDF Diabetes Atlas 2010. http://www.idf.org/atlasmap/atlasmap.2. Stratton, I. et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000; 321: 405-412.
Latest News
28th January 2012
CHMP recommends Remicade (Janssen Biologic) for Paediatric Ulcerative Colitis Page
The CHMP has issued a positive opinion for Remicade (infliximab) from Janssen Biologic for the treatment of severely active Ulcerative Colitis in paediatric patients aged between six to 17 who have had an inadequate response to conventional therapy, or who or intolerant to, or have medical contraindications to these therapies. The recommendation is based on a Phase III randomised, open-label trial in 60 children showing that the drug produced a clinical response in 73% of subjects by week eight, and maintained remission in up to 38% of responders by week 54. Remicade is approved for this indication in the USA and Canada.
Picato (Leo Pharma) is FDA approved for Actinic KeratosisDermatology Page
The FDA has approved Picato (ingenol mebutate) gel in the 0.015%/0.05% strength from Leo Pharma for the topical treatment of Actinic Keratosis which is a precancerous condition resulting from cumulative sun exposure that has the potential to lead to squamous cell carcinoma. The drug is the first and only topical therapy available in the USA for Actinic Keratosis that can be used for as little as two or three days.
Afinitor (Novartis) fails Gastric Cancer studyOncology Page
Novartis reported the results of the 656 patient GRANITE-1 Phase III randomised, double-blind, multicentre study which showed that Afinitor (everolimus) monotherapy did not significantly improve overall survival in patients with advanced Gastric Cancer who had previously been treated with one or two lines of systemic chemotherapy.
